Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study.

AIMS We tested the hypothesis that higher levels of plasma triglycerides and remnant cholesterol are observationally and genetically associated with increased risk of aortic valve stenosis. METHODS AND RESULTS We included 108 559 individuals from the Copenhagen General Population Study. Plasma triglycerides, remnant cholesterol (total cholesterol minus low-density lipoprotein and high-density lipoprotein cholesterol), and 16 genetic variants causing such increased or decreased levels were determined. Incident aortic valve stenosis occurred in 1593 individuals. Observationally compared to individuals with triglycerides <1 mmol/L (<89 mg/dL), the multifactorially adjusted hazard ratio for aortic valve stenosis was 1.02 [95% confidence interval (CI) 0.87-1.19] for individuals with triglycerides of 1.0-1.9 mmol/L (89-176 mg/dL), 1.22 (1.02-1.46) for 2.0-2.9 mmol/L (177-265 mg/dL), 1.40 (1.11-1.77) for 3.0-3.9 mmol/L (266-353 mg/dL), 1.29 (0.88-1.90) for 4.0-4.9 mmol/L (354-442 mg/dL), and 1.52 (1.02-2.27) for individuals with triglycerides ≥5 mmol/L (≥443 mg/dL). By age 85, the cumulative incidence of aortic valve stenosis was 5.1% for individuals with plasma triglycerides <2.0 mmol/L (77 mg/dL), 6.5% at 2.0-4.9 mmol/L (177-442 mg/dL), and 8.2% for individuals with plasma triglycerides ≥5.0 mmol/L (443 mg/dL). The corresponding values for remnant cholesterol categories were 4.8% for <0.5 mmol/L (19 mg/dL), 5.6% for 0.5-1.4 mmol/L (19-57 mg/dL), and 7.4% for ≥1.5 mmol/L (58 mg/dL). Genetically, compared to individuals with allele score 13-16, odds ratios for aortic valve stenosis were 1.30 (95% CI 1.20-1.42; Δtriglycerides +12%; Δremnant cholesterol +11%) for allele score 17-18, 1.41 (1.31-1.52; +25%; +22%) for allele score 19-20, and 1.51 (1.22-1.86; +51%; +44%) for individuals with allele score 21-23. CONCLUSION Higher triglycerides and remnant cholesterol were observationally and genetically associated with increased risk of aortic valve stenosis.

[1]  M. Sabatine,et al.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.

[2]  A. Kutikhin,et al.  Development of calcific aortic valve disease: Do we know enough for new clinical trials? , 2019, Journal of molecular and cellular cardiology.

[3]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[4]  S. Larsson,et al.  Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study , 2019, European heart journal.

[5]  B. Nordestgaard,et al.  Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population , 2019, Annals of neurology.

[6]  B. Nordestgaard,et al.  Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population. , 2019, Clinical chemistry.

[7]  J. Lincoln,et al.  The Genetic Regulation of Aortic Valve Development and Calcific Disease , 2018, Front. Cardiovasc. Med..

[8]  A. Ravani,et al.  Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments , 2018, Pharmacological research.

[9]  B. Nordestgaard,et al.  APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137 895 Individuals , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[10]  B. Nordestgaard,et al.  Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study. , 2018, Clinical chemistry.

[11]  B. Nordestgaard A Test in Context: Lipid Profile, Fasting Versus Nonfasting. , 2017, Journal of the American College of Cardiology.

[12]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[13]  Eliot A Brinton,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[14]  S. Larsson,et al.  Overall and abdominal obesity and incident aortic valve stenosis: two prospective cohort studies , 2017, European heart journal.

[15]  Daniel R. Lavage,et al.  Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease , 2017, JAMA.

[16]  M. Scartezini,et al.  Positioning about the Flexibility of Fasting for Lipid Profiling , 2017, Arquivos brasileiros de cardiologia.

[17]  G. Francis,et al.  2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. , 2016, The Canadian journal of cardiology.

[18]  D. Gudbjartsson,et al.  Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease , 2016, Nature Genetics.

[19]  P. McFarlane,et al.  Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.

[20]  F. Kronenberg,et al.  Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.

[21]  Dermot F. Reilly,et al.  Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease , 2018 .

[22]  Alexander E. Lopez,et al.  Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.

[23]  B. Nordestgaard Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[24]  M. Reilly,et al.  From Loci to Biology: Functional Genomics of Genome-Wide Association for Coronary Disease. , 2016, Circulation research.

[25]  P. O'Malley,et al.  Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline , 2015, Annals of Internal Medicine.

[26]  M. Dweck,et al.  Calcification in Aortic Stenosis: The Skeleton Key. , 2015, Journal of the American College of Cardiology.

[27]  B. Nordestgaard,et al.  Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population. , 2015, The Journal of clinical endocrinology and metabolism.

[28]  Vilmundur Gudnason,et al.  Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. , 2014, JAMA.

[29]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[30]  B. Nordestgaard,et al.  Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.

[31]  He Zhang,et al.  Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.

[32]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[33]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[34]  B. Nordestgaard,et al.  Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.

[35]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[36]  J. Després,et al.  Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling , 2013, European journal of clinical investigation.

[37]  Kathleen F. Kerr,et al.  Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.

[38]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[39]  H. Schirmer,et al.  The evolving epidemiology of valvular aortic stenosis. The Tromsø Study , 2012, Heart.

[40]  P. Heidenreich,et al.  The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality. , 2012, The Journal of heart valve disease.

[41]  R. Eckel,et al.  Triglycerides and Heart Disease: Still a Hypothesis? , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[42]  P. Schnohr,et al.  Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow‐up , 2011, Journal of internal medicine.

[43]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[44]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[45]  B. Nordestgaard,et al.  Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population , 2011, Annals of neurology.

[46]  B. Nordestgaard,et al.  TRIB1 and GCKR Polymorphisms, Lipid Levels, and Risk of Ischemic Heart Disease in the General Population , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[47]  K. Teo,et al.  Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.

[48]  H. Hense,et al.  Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. , 2009, European heart journal.

[49]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of ischemic stroke in the general population. , 2008, JAMA.

[50]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[51]  G. Feuchtner,et al.  Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). , 2008, The American journal of cardiology.

[52]  G. Watts,et al.  Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. , 2008, Clinical science.

[53]  J. Després,et al.  Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[54]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[55]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[56]  R. Kronmal,et al.  Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis , 2006, Circulation.

[57]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[58]  B. Nordestgaard,et al.  Lipoprotein Lipase Mutations, Plasma Lipids and Lipoproteins, and Risk of Ischemic Heart Disease A Meta-Analysis , 1999 .

[59]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[60]  Catherine M. Otto,et al.  Clinical Factors Associated With Calcific Aortic Valve Disease , 1997 .

[61]  C. Otto,et al.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[62]  A. Gown,et al.  Characterization of the Early Lesion of ‘Degenerative’ Valvular Aortic Stenosis: Histological and Immunohistochemical Studies , 1994, Circulation.

[63]  J. Parks,et al.  Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans. , 1993, Journal of lipid research.

[64]  A G Babiker,et al.  Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. , 1991, Statistics in medicine.

[65]  R. Norum,et al.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. , 1986, The Journal of clinical investigation.